STAT+: Disappointing tumor responses, more side effects, seen with latest Amgen KRAS combination studies

Amgen on Thursday reported preliminary results from two clinical trials of its KRAS-blocking cancer drug Lumakras, which showed disappointing tumor response and more side effects.

Click to view original post